REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/regeneron-ph ...

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 10, 2025. SO WHAT: If you purchased Regeneron securitie ...

Group 1 - Investors who lost money on Regeneron Pharmaceuticals, Inc. (REGN) are encouraged to contact Levi & Korsinsky regarding a pending class action lawsuit [1] - The class action is aimed at addressing potential losses incurred by investors due to undisclosed information or misleading statements related to Regeneron's performance [1] - The announcement highlights the importance of investor awareness and the legal recourse available for those affected by the company's actions [1] Group 2 - The article emphasizes the ongoing legal challenges faced by Regeneron Pharmaceuticals, which may impact investor confidence and stock performance [1] - It suggests that the outcome of the class action could have significant implications for the company's reputation and financial standing [1] - The situation underscores the broader context of investor protection and corporate accountability within the pharmaceutical industry [1]

Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN ...

SAN DIEGO, Jan. 16, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit.  Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Rege ...

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc. ...

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=123059&from=4CLASS ...

Core Viewpoint - Regeneron Pharmaceuticals, Inc. is facing a securities fraud class action following a significant drop in its share price, which resulted in a loss of approximately $9 billion in market value due to alleged misleading statements regarding its EYLEA product [1][5]. Group 1: Legal Issues and Investigations - Hagens Berman has initiated an investigation into Regeneron for potentially misleading investors about its marketing and reimbursement practices related to EYLEA, urging affected investors to report their losses [2][6]. - The class action lawsuit focuses on Regeneron's compliance with regulations concerning Medicare reimbursement claims, particularly for EYLEA [3]. - The complaint alleges that Regeneron made false statements and failed to disclose various practices that misrepresented the pricing and sales of EYLEA, including undisclosed credit card fees that effectively lowered the selling price [4]. Group 2: Financial Impact and Company Performance - On October 31, 2024, Regeneron reported disappointing Q3 2024 financial results, with U.S. net sales for EYLEA and EYLEA HD products increasing only 3% year-over-year, attributed to lower net selling prices and pricing pressure in the anti-VEGF category [5]. - The announcement of these results led to a more than 9% decline in Regeneron's share price on the same day [5].

Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its product Eylea during the Class Period from November 2, 2023, to October 30, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Regeneron made false statements and failed to disclose that it paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card purchases [5]. - These undisclosed payments allegedly subsidized customer prices, leading to a price concession that lowered Eylea's selling price, which misled investors about the actual sales performance of Eylea [5]. - The lawsuit also alleges that Regeneron overstated the Average Sales Price (ASP) reported to federal agencies, violating the False Claims Act, and that positive statements about the company's business were materially misleading [5]. Group 2: Participation Information - Investors who purchased Regeneron securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].